The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

GLP-1 agonists, also known as incretin mimetics ... are predominantly related to the gastrointestinal system -- for example, nausea, constipation, diarrhea or belching. For most patients, these ...

There’s no denying that GLP-1 medications like Ozempic and Wegovy are having a moment. You’ve probably seen the headlines, ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise ... need" to compound – for example, if there is a shortage in ...

Patients taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs) can lose between 5% ... Talking to patients about where they grocery shop, for example, can be helpful, said Ivania Rizo ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... with some drugs in the oral GLP-1 class. For example, Novo Nordisk's oral formulation of semaglutide ...